Safety and efficacy of single agent rovalpituzumab tesirine in small cell lung cancer (SCLC)
1 Vues
• 07/14/23
0
0
Intégrer
administrator
Les abonnés
Press brief by Charles Rudin, MD, PhD of the Memorial Sloan Kettering Cancer Center, New York, NY, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.
Montre plus
Commentaires de Facebook
SORT BY-
Meilleures Commentaires
-
Derniers Commentaires